Summary of the 2025 Semi-Annual Report of Zhejiang Huahai Pharmaceutical Co., Ltd.
Zhejiang Huahai Pharmaceutical Co., Ltd. 2025 Semi-annual Report Summary Company Code: 600521 Company Abbreviation: Huahai Pharmaceutical
Zhejiang Huahai Pharmaceutical Co., Ltd.
2025 Interim Report Summary
Section 1 Important Tips
1.1 The summary of this semi-annual report comes from the full text of the semi-annual report. In order to fully understand the company's operating results, financial status and future development plans, investors should go to the Shanghai Stock Exchange website www.sse.com.cn to carefully read the full text of the semi-annual report.
1.2 The company’s board of directors, directors and senior managers guarantee the authenticity, accuracy and completeness of the contents of the semi-annual report and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability.
1.3 All directors of the company shall attend the board meeting.
1.4 This semi-annual report has not been audited.
1.5 The profit distribution plan for the reporting period or the plan for converting public reserve funds into share capital passed by the board of directors
None
Section 2 Basic Information of the Company
2.1 Company Profile
Company Stock Profile
Stock type Stock listing exchange Stock abbreviation Stock code Stock abbreviation before change A shares Shanghai Stock Exchange Huahai Pharmaceutical 600521 Not applicable
Contact and Contact Information Secretary of the Board Securities Affairs Representative
Name Zhu Yonghua Jin Min
Phone 0576-85991096 0576-85991096
Office address No. 88, Xunda Road, Xunqiao Town, Linhai City, Taizhou City, Zhejiang Province No. 88, Xunda Road, Xunqiao Town, Linhai City, Taizhou City, Zhejiang Province E-mail [email protected] [email protected]
2.2 Main financial data
Unit: Yuan Currency: RMB
End of the reporting period End of the previous year End of the reporting period Increase/decrease (%) in total assets at the end of the reporting period compared with the end of the previous year 21,265,898,469.48 20,261,354,969.92 4.96 Net assets attributable to shareholders of listed companies 9,910,300,224.43 8,897,779,286.94 11.38
This reporting period The same period last year This reporting period increased or decreased (%) operating income compared with the same period last year 4,516,353,788.97 5,128,307,063.04 -11.93 Total profit 542,860,973.47 956,425,345.50 -43.24Net profit attributable to shareholders of listed companies 409,487,616.19 748,566,030.81 -45.30 Deduction of non-tax attributable to shareholders of listed companies 363,424,637.01 764,852,741.61 -52.48
Summary of the 2025 Semi-Annual Report of Zhejiang Huahai Pharmaceutical Co., Ltd.
Net profit from recurring gains and losses
Net cash flow generated from operating activities 369,637,712.53 1,297,827,513.80 -71.52 Weighted average return on equity (%) 4.35 8.88 Decrease by 4.53 percentage points Basic earnings per share (yuan/share) 0.28 0.52 -46.15 Diluted earnings per share (yuan/share) 0.28 0.52 -46.15
2.3 List of shareholdings of the top 10 shareholders
Unit: Share
Total number of shareholders (households) as of the end of the reporting period 52,413 Total number of preference shareholders (households) with restored voting rights as of the end of the reporting period 0 Shareholdings of the top 10 shareholders
Limited holding
Shareholding ratio Shareholding Name of shareholder pledged, marked or frozen Nature of shareholder Conditions for sale
Example (%) Quantity Number of shares
Number of shares
Chen Baohua Domestic natural person 24.64 368,877,935 0 None 0 Zhou Minghua Domestic natural person 14.99 224,418,890 0 Pledge 78,980,000 Industrial and Commercial Bank of China Co., Ltd. - China Europe Healthcare
Others 2.22 33,246,818 0 None 0 Hybrid securities investment funds
Jiangyin Miledu Private Equity Fund Management Partnership (Limited Partnership)
Others 1.75 26,250,000 0 None 0 units) - Miletus New Power Private Securities Investment Fund
Hong Kong Securities Clearing Company Limited Others 1.26 18,897,499 0 None 0 Cathay Asset Management Co., Ltd. - Social Security Fund 2103 Portfolio Others 1.14 17,026,869 0 None 0 Agricultural Bank of China Co., Ltd. - CSI 500 Trading Type
Others 0.90 13,417,628 0 None 0 Open-ended index securities investment fund
Cathay Jiatai stock-specific pension product – China Merchants Bank
Others 0.84 12,567,271 0 None 0 Co., Ltd.
Taizhou Financial Investment Group Co., Ltd. State-owned legal person 0.83 12,462,871 0 None 0Wu Hong Domestic natural person 0.61 9,200,000 0 None 0Explanation of related relationships or concerted actions among the above shareholders The company does not know whether there is any related relationship among the top ten shareholders subject to sales restrictions
Or they are persons acting in concert as stipulated in the "Measures for the Administration of Acquisitions of Listed Companies". Description of preference shareholders with restored voting rights and number of shares held None
2.4 Total number of preference shareholders and top 10 preference shareholders as of the end of the reporting period
□Applicable √Not applicable
2.5 Changes in controlling shareholders or actual controllers
□Applicable √Not applicable
2.6 Status of bonds existing on the date of approval of the semi-annual report
□Applicable √Not applicable
Summary of the 2025 Semi-Annual Report of Zhejiang Huahai Pharmaceutical Co., Ltd.
Section 3 Important Matters
The company shall, in accordance with the principle of materiality, explain the major changes in the company's operating conditions during the reporting period, as well as the matters that occurred during the reporting period that have a significant impact on the company's operating conditions and are expected to have a significant impact in the future.
□Applicable √Not applicable
Legal representative: Chen Baohua
Board approval submission date: August 25, 2025